Breast cancer is the most common type of malignancies in women worldwide, and genotoxic chemotherapeutic drugs are effective by causing DNA damage in cancer cells. However, >90% of patients with metastatic cancer are resistant to chemotherapy. The Forkhead box M1 (FOXM1) transcription factor plays a pivotal role in the resistance of breast cancer cells to chemotherapy by promoting DNA damage repair following genotoxic drug treatment. The aim of the present study was to investigate the inhibition of the FOXM1 protein by thiostrepton, a natural antibiotic produced by the Streptomyces species. Experimental studies were designed to examine the effectiveness of thiostrepton in downregulating FOXM1 mRNA expression and activity, leading to senesce...
AbstractDeregulation of transcription factor (TF) networks is emerging as a major pathogenic event i...
The forkhead box M1 (FOXM1) transcription factor has a central role in genotoxic agent response in b...
Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their ...
The Forkhead Box M1 (FOXM1) transcription factor is an important master cell cycle regulator that c...
PhD ThesisThe transcription factor Forkhead Box Protein M1 (FOXM1) regulates several genes involved ...
Forkhead box M1 (FoxM1) oncogenic transcription factor represents an attractive therapeutic target i...
FoxM1 is an oncogenic Forkhead transcription factor that is overexpressed in ovarian cancer. However...
FoxM1 is an oncogenic Forkhead transcription factor that is overexpressed in ovarian cancer. However...
Breast cancer is the most commonly diagnosed cancer in women worldwide. In the UK, there is 1 in 8 ...
Background. The forkhead box M1 (FOXM1) transcription factor plays an important role in the metastas...
Forkhead box M1 (FOXM1) is a member of the conserved forkhead box (FOX) transcription factor family....
Forkhead box M1 (FoxM1) is a transcription factor that plays an important role in the etiology of ma...
Endocrine agents have become the primary adjuvant treatment for breast cancer. In addition to endocr...
Resistance to 5-Fluoruracil (5-FU) has been linked to elevated expression of the main target, thymid...
AbstractDeregulation of transcription factor (TF) networks is emerging as a major pathogenic event i...
AbstractDeregulation of transcription factor (TF) networks is emerging as a major pathogenic event i...
The forkhead box M1 (FOXM1) transcription factor has a central role in genotoxic agent response in b...
Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their ...
The Forkhead Box M1 (FOXM1) transcription factor is an important master cell cycle regulator that c...
PhD ThesisThe transcription factor Forkhead Box Protein M1 (FOXM1) regulates several genes involved ...
Forkhead box M1 (FoxM1) oncogenic transcription factor represents an attractive therapeutic target i...
FoxM1 is an oncogenic Forkhead transcription factor that is overexpressed in ovarian cancer. However...
FoxM1 is an oncogenic Forkhead transcription factor that is overexpressed in ovarian cancer. However...
Breast cancer is the most commonly diagnosed cancer in women worldwide. In the UK, there is 1 in 8 ...
Background. The forkhead box M1 (FOXM1) transcription factor plays an important role in the metastas...
Forkhead box M1 (FOXM1) is a member of the conserved forkhead box (FOX) transcription factor family....
Forkhead box M1 (FoxM1) is a transcription factor that plays an important role in the etiology of ma...
Endocrine agents have become the primary adjuvant treatment for breast cancer. In addition to endocr...
Resistance to 5-Fluoruracil (5-FU) has been linked to elevated expression of the main target, thymid...
AbstractDeregulation of transcription factor (TF) networks is emerging as a major pathogenic event i...
AbstractDeregulation of transcription factor (TF) networks is emerging as a major pathogenic event i...
The forkhead box M1 (FOXM1) transcription factor has a central role in genotoxic agent response in b...
Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their ...